Adaptimmune Therapeutics plc Market Cap ($42.94 Million)
Market Cap & Net Worth: Adaptimmune Therapeutics plc (473A)
Adaptimmune Therapeutics plc market cap. Adaptimmune Therapeutics plc (F:473A) has a market capitalization of $42.94 Million (€36.73 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #22280 globally and #1968 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adaptimmune Therapeutics plc's stock price €0.16 by its total outstanding shares 265051591 (265.05 Million). Also see Adaptimmune Therapeutics plc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Adaptimmune Therapeutics plc Market Cap History (2015–2025)
Adaptimmune Therapeutics plc market cap history from 2015 to 2025. Data shows change from $3.17 Billion to $50.20 Million (-31.07% CAGR). Check Adaptimmune Therapeutics plc stock price for real-time trading data and today's change.
Adaptimmune Therapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adaptimmune Therapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Adaptimmune Therapeutics plc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.91x
Adaptimmune Therapeutics plc's market cap is 0.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.17 Billion | $14.20 Million | -$71.58 Million | 82.61x | N/A |
| 2017 | $1.79 Billion | $37.83 Million | -$70.14 Million | 47.19x | N/A |
| 2018 | $1.29 Billion | $59.51 Million | -$95.51 Million | 21.66x | N/A |
| 2019 | $393.54 Million | $1.12 Million | -$137.16 Million | 350.75x | N/A |
| 2020 | $1.29 Billion | $3.96 Million | -$130.09 Million | 325.69x | N/A |
| 2021 | $997.79 Million | $6.15 Million | -$158.09 Million | 162.27x | N/A |
| 2022 | $390.44 Million | $27.15 Million | -$165.46 Million | 14.38x | N/A |
| 2023 | $181.28 Million | $60.28 Million | -$113.87 Million | 3.01x | N/A |
| 2024 | $162.68 Million | $178.03 Million | -$70.81 Million | 0.91x | N/A |
Competitor Companies of 473A by Market Capitalization
Companies near Adaptimmune Therapeutics plc in the global market cap rankings as of November 4, 2026. Also see 473A asset base for a full breakdown of the balance sheet.
Key companies related to Adaptimmune Therapeutics plc by market ranking:
- Schwälbchen Molkerei Jakob Berz AG (F:SMB): Ranked #22271 globally with a market cap of $43.00 Million USD ( €36.78 Million EUR).
- JSS Real Estate SOCIMI SA (MC:YJSS): Ranked #22272 globally with a market cap of $43.00 Million USD ( €36.78 Million EUR).
- Arizona Gold & Silver Inc. (V:AZS): Ranked #22281 globally with a market cap of $42.93 Million USD ( CA$59.35 Million CAD).
- Brunswick Exploration Inc (V:BRW): Ranked #22282 globally with a market cap of $42.90 Million USD ( CA$59.30 Million CAD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #22271 | Schwälbchen Molkerei Jakob Berz AG | F:SMB | $43.00 Million | €40.00 |
| #22272 | JSS Real Estate SOCIMI SA | MC:YJSS | $43.00 Million | €8.60 |
| #22281 | Arizona Gold & Silver Inc. | V:AZS | $42.93 Million | CA$0.52 |
| #22282 | Brunswick Exploration Inc | V:BRW | $42.90 Million | CA$0.21 |
Market Capitalization of Adaptimmune Therapeutics plc (2015–2025)
Market capitalization of Adaptimmune Therapeutics plc from 2015 to today. Between 2015 and today, Adaptimmune Therapeutics plc's market cap moved from $3.17 Billion to $ 50.20 Million, with a yearly change of -31.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €50.20 Million | -69.14% |
| 2024 | €162.68 Million | -10.26% |
| 2023 | €181.28 Million | -53.57% |
| 2022 | €390.44 Million | -60.87% |
| 2021 | €997.79 Million | -22.60% |
| 2020 | €1.29 Billion | +227.56% |
| 2019 | €393.54 Million | -69.47% |
| 2018 | €1.29 Billion | -27.80% |
| 2017 | €1.79 Billion | +52.23% |
| 2016 | €1.17 Billion | -62.95% |
| 2015 | €3.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 19th, 2026 the market cap of Adaptimmune Therapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $42.94 Million USD |
| MoneyControl | $42.94 Million USD |
| MarketWatch | $42.94 Million USD |
| marketcap.company | $42.94 Million USD |
| Reuters | $42.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more